Posted March 01, 2018 10:27:17The stock is up more than 60% since April 2017.
Investors are looking for an investment opportunity and have poured hundreds of millions into the company.
The company has a large market cap and it is currently worth $4.3 billion.
But if you are looking to buy Viscral, you may want to look elsewhere.
Viscral’s valuation is a lot higher than most of the companies in the space.
The firm is valued at $2.4 billion by BNY Mellon, according to Forbes.
The stock has more than doubled in value since the company’s IPO in 2015.
The latest earnings release has shown that the company has more revenue than it did in 2019.
Viscal raised $9 million in September.
Visceral recently acquired a new $500 million loan facility from the US Federal Reserve, according the New York Times.
Another $500M loan to the company is in place.
The firm’s CEO Charles Schwab is currently a director of Viscerals private equity firm.
He owns about 70% of Visions Holdings, the holding company of Viceroy.
Schwab has also been involved in other investment deals.
The new loan may help Viscera gain more traction in the markets.
Viceroy, Viscercas most valuable asset is Viscals current portfolio of debt instruments, according Bloomberg.
The loans are worth about $600 million and $1.1 billion, according a regulatory filing with the SEC.
Visker has a market cap of $3.8 billion, which is the second largest in the business behind Tesla.
The shares are up almost 100% since the end of April 2017 and are trading at $1,050.
VistraX is a healthcare software startup focused on treating high-risk patients.
The founders are a trio of doctors in the United States.
The venture raised $1 million in January.
The company has an impressive product that is used to treat a wide range of medical conditions.
Its main competitors are private equity firms such as KKR and DFJ.
Vistra X raised $2 million in August and it will have about $7 million in its second round of funding in 2018.